Komori
Financial results presentation4971MEC COMPANY LTD.Materials and Chemicals

2025年12月期第2四半期（中間期）決算説明会資料

2025年12月期中間期は、薬品の売上・出荷量が伸びたことで売上高と営業利益が前年同期を上回った。一方、為替の影響などにより経常利益は減少し、通期予想は売上高2,000億円ではなく200億円、営業利益50億円、経常利益51億円、純利益36億円として示されている。

Worth reading
66In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
504
¥ million (year-on-year increase in consolidated net sales)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Financial results presentation2025年12月期 第2四半期（中間期）12 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥9,387 million+5.7%
Operating profit¥2,440 million+3.3%
Ordinary income¥2,493 million-5.6%
Net income¥1,893 million+0.2%
Gross Profit Margin61.8 %
Operating profit margin26 %
Selling, general and administrative expenses¥3,363 million
Results for the three months of the current quarter
Net Sales
¥4,963 million
Operating profit
¥1,347 million
Operating profit margin
27.1 %
Full-year earnings forecast
Net Sales
¥20,000 million
Operating profit
¥5,000 million
Ordinary income
¥5,100 million
Net income
¥3,600 million
Earnings per share
¥192.26
Dividend per share
¥55
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales46.9 %
Operating profit48.8 %
Ordinary income48.9 %
Net income52.6 %
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net Sales密着向上剤、エッチング剤、その他薬品、機械売上、資材売上、その他売上、為替の影響（個別金額はNot disclosed）
Operating profit薬品売上・数量、薬品粗利益率、機械売上、機械粗利益率、資材およびその他売上、資材およびその他粗利益率、販管費、為替の影響（個別金額はNot disclosed）
Year-on-year increase
Net Sales¥504 million
Operating profit¥77 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate
NTD¥4.76
RMB¥21.08
HKD¥19.48
THB¥4.22
EUR¥164.84
USD¥152.33
Business Environment短期的には回復基調にある半導体市況の影響を見込む
New initiatives
  • 北九州工場を新設し、2026年12月稼働予定、最大生産能力2,500t/月を計画
  • APシリーズなど化学密着技術をPKG基板・高周波基板・インターポーザーへ展開
  • 生成AI・データセンター関連など新領域への技術展開
Key KPIsA metric the company considers important as a management benchmark.
  • 薬品売上高¥9,025 million
    Year on year against the same period last year+7.6%
  • Shipment volume21,985 ton
    Year on year against the same period last year+8.6%
  • Overseas revenue ratio67.1 %
  • 海外売上高比率（国内代理店経由の海外顧客を含む）81.2 %
    Year on year against the same period last year+79.5%
  • Production Capacity8,100 t/month
    Year on year against the same period last year+12.5%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Shipment volume
21,985 ton+8.6%
Medium-term management plan targets
Plan name2030年ビジョン中期経営計画Phase2（2025〜2027年）
ROEAt least 10%
Consolidated payout ratio30% target
Capital expenditures3カ年累計約80億円
国内Scope1・2排出量2030年までに2017年度比で実質50％削減
Financial targets
ROE targetAt least 10%
2025年12月期ROE予想12.8 %
Number of employees
Consolidated480 people
Standalone277 people
Record date2024年12月31日
Capital expenditures
¥2,097 million
Details2025年12月期予想。北九州工場関連設備投資額
Annual Dividend
¥55 per share
Interim25
End of period30
Payout ratio
30 %
DetailsTargets
Acquisition of treasury shares
Policy状況に応じて機動的に実施
Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period Covered2025年12月期 第2四半期（中間期）
Net Sales¥9,387 million (YoY +5.7%)
Operating profit¥2,440 million (YoY +3.3%)
Ordinary income¥2,493 million (YoY -5.6%)
Net income¥1,893 million (YoY +0.2%)
Gross Profit Margin61.8 %
Operating profit margin26 %
Selling, general and administrative expenses¥3,363 million
Results for the three months of the current quarterNet Sales ¥4,963 million / Operating profit ¥1,347 million / Operating profit margin 27.1 %
Full-year earnings forecastNet Sales ¥20,000 million / Operating profit ¥5,000 million / Ordinary income ¥5,100 million / Net income ¥3,600 million / Earnings per share ¥192.26 / Dividend per share ¥55
Progress against full-year forecastNet Sales 46.9 % / Operating profit 48.8 % / Ordinary income 48.9 % / Net income 52.6 %
Breakdown of Factors Affecting the ChangeNet Sales 密着向上剤、エッチング剤、その他薬品、機械売上、資材売上、その他売上、為替の影響（個別金額はNot disclosed） / Operating profit 薬品売上・数量、薬品粗利益率、機械売上、機械粗利益率、資材およびその他売上、資材およびその他粗利益率、販管費、為替の影響（個別金額はNot disclosed） / Year-on-year increase Net Sales ¥504 million / Operating profit ¥77 million
Key KPIsIndicator name 薬品売上高 / Value ¥9,025 million / Year on year against the same period last year ¥7.6 million, Indicator name Shipment volume / Value 21,985 ton / Year on year against the same period last year 8.6 ton, Indicator name Overseas revenue ratio / Value 67.1 % / Year on year against the same period last year Not disclosed, Indicator name 海外売上高比率（国内代理店経由の海外顧客を含む） / Value 81.2 % / Year on year against the same period last year 79.5 %, Indicator name Production Capacity / Value 8,100 t/month / Year on year against the same period last year 12.5 t/month
Unit price and quantity metricsShipment volume 21,985 ton (YoY +8.6%) / Unit price Not disclosed
Number of employeesConsolidated 480 people / Standalone 277 people / Record date 2024年12月31日
Assumptions Underlying the Business OutlookExchange rate NTD ¥4.76 / RMB ¥21.08 / HKD ¥19.48 / THB ¥4.22 / EUR ¥164.84 / USD ¥152.33 / Business Environment 短期的には回復基調にある半導体市況の影響を見込む
Medium-term management plan targetsPlan name 2030年ビジョン中期経営計画Phase2（2025〜2027年） / ROE At least 10% / Consolidated payout ratio 30% target / Capital expenditures 3カ年累計約80億円 / 国内Scope1・2排出量 2030年までに2017年度比で実質50％削減
Financial targetsROE target At least 10% / 2025年12月期ROE予想 12.8 %
Annual Dividend¥55 per share
Payout ratio30 %
Acquisition of treasury sharesPolicy 状況に応じて機動的に実施 / Buyback limit Not disclosed
Capital expenditures¥2,097 million
New initiatives北九州工場を新設し、2026年12月稼働予定、最大生産能力2,500t/月を計画, APシリーズなど化学密着技術をPKG基板・高周波基板・インターポーザーへ展開, 生成AI・データセンター関連など新領域への技術展開
Items this document does not state (7)
Self-assessment against the planSegment resultsNumber of stores and locationsRisk amount incorporated into the outlookOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

薬品売上高が前年同期比7.6％増加し、出荷量も8.6％増加したことが主な増収要因。営業利益については、薬品の売上・数量、機械売上、資材・その他売上、各品種の粗利益率、販管費、為替の影響などを要因として示している。為替の影響は前年同期比で売上高110百万円減少、営業利益70百万円減少と説明している。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
2025年12月期第2四半期（中間期）決算説明会資料 | MEC COMPANY LTD. (4971) timely disclosure | Komori